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Abstract In view of the associations of “a disintegrin and
metalloprotease” (ADAM) with respiratory diseases, we
assessed the expression of various ADAMs in human lung
tissue. Lung tissue was obtained from nine individuals who
underwent surgery for lung cancer or underwent lung
transplantation for emphysema. Also, 16HBE 14o- (human
bronchial epithelial) and A549 (alveolar type II epithelium-
like) cell lines were used. Immunohistochemistry was
performed with antibodies recognizing different ADAM
domains. The ADAMs were typically distributed over the
bronchial epithelium. ADAM8 and ADAM10 were
expressed diffusely in all layers of the epithelium. ADAM9,
ADAM17, and ADAM19 were predominantly expressed in
the apical part of the epithelium, and ADAM33 was
predominantly and strongly expressed in basal epithelial
cells. In smooth muscle, ADAM19 and ADAM17 were
strongly expressed, as was ADAM33, though this expres-
sion was weaker. ADAM33 was strongly expressed in
vascular endothelium. All ADAMs were generally
expressed in inflammatory cells. The typical distribution
of ADAMs in the lung, especially in the epithelium, is
interesting and suggests a localized function. As most
ADAMs are involved in release of (pro-) inflammatory
mediators and growth factors, they may play an important
role in the first line of defense and in initiation of repair
events in the airways.
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Introduction
Although the “a disintegrin and metalloprotease” (ADAM)
molecules are known for quite some time, it has more
recently become clear that these molecules play a central
role in many normal and abnormal biological processes.
ADAMs are thought to be implicated in the control of
membrane fusion and in cell–cell and cell–matrix inter-
actions by the binding capacity of the disintegrin domain to
specific integrins [1]. ADAMs have also been demonstrated
to play a role in the shedding of proprotein ectodomains
like membrane-anchored cytokines and growth factors [1].
The ADAM molecules are members of a disintegrin and
metalloprotease family, which are type I transmembrane
zymogen glycoproteins that typically contain a N-terminal
secretion signal domain, an epidermal growth factor (EGF)-
like-transmembrane part, and a cytoplasmic (C-terminal)
domain [2, 3]. The EGF-like transmembrane domain has a
prodomain, a metalloprotease-, a disintegrin-, and a
cysteine-rich domain. For several ADAMs, the specific
substrates have not been identified yet. The most exten-
sively studied ADAM molecule is ADAM17 (also known
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as tumor necrosis factor (TNF)-alpha-converting enzyme
(TACE)), which cleaves membrane-bound TNF-alpha,
thereby releasing this molecule in its active, soluble form
[4].
Because of their biological role in humans, further
knowledge about the localization and function of ADAM-
family members is also of importance to understand their
role in disease development. In recent studies, ADAMs
have been suggested to play a role in a pulmonary disease
like asthma [5–9] but also in interstitial lung disease [10],
eosinophilic pneumonia [11], and lung cancer [12]. More-
over, single nucleotide polymorphisms (SNPs) in ADAM33
have been found to be associated with asthma development
and progression [7] as well as with progressive lung
function loss in the general population and development
of COPD [13, 14]. In view of the association of ADAMs
with respiratory diseases, our study was undertaken to
assess the expression and localization of various ADAMs
with metalloproteinase activity (ADAM8, ADAM9, AD-
AM10, ADAM17, ADAM19, and ADAM33) in human
lung tissue. To verify epithelial localization, ADAM
expression was also assessed in a human bronchial and
alveolar epithelial cell line.
Materials and methods
Human lung tissue
Lung tissue was obtained from six individuals (age median
[range], 65 [62–74]; four men, two women; three current
smokers, two ex-smokers, one non-smoker) who underwent
surgery for lung cancer and from three patients (age median
[range], 61 [53–70]; two men, one woman, all ex-smokers)
that underwent lung transplantation for emphysema. Lung
tissue was taken as far as possible from the tumor and was
normal on inspection. The lung tissue was only included in
the study after exclusion of any lung pathology (for the
emphysema cases, any lung pathology other than seen in
COPD) as based on clinical data, lung function, and routine
histological examination of lung tissue performed by an
experienced pulmonary pathologist (WT). The procedures
followed were in accordance with the ethical local and
national guidelines.
Immunohistochemistry
Antibodies recognizing different domains of the ADAMs
were commercially obtained (Table 1). Frozen lung sections
were cut at 4 μm, dried for 20 min, and fixed in acetone
(100%). Sections were incubated for 1 h with rabbit or goat
antibodies for ADAMs in a proper dilution as determined
previously. Endogenous peroxidase was blocked with
0.075% H2O2 in phosphate-buffered saline (PBS, pH7.4)
for 30 min. Subsequently, sections incubated with rabbit
antibodies were incubated for 30 min with peroxidase
conjugated goat-anti-rabbit (GARpo) anti-serum, followed
by incubation with rabbit-anti-goat (RAGpo). Sections
incubated with goat antibodies were incubated with
RAGpo, followed by incubation with GARpo. Sections
were rinsed in PBS for 5 min after each incubation step.
Peroxidase activity was demonstrated by immersing the
slides in sodium acetate buffer containing 0.2 mg/ml 3-
amino-9-ethyl-carbazole (Sigma-Aldrich Chemie BV,
Zwijndrecht, The Netherlands) and 0.03% H2O2 for
15 min. Sections were counterstained with Mayers hema-
toxylin for 1 min. Immunohistology staining results were
evaluated by three independent observers. Staining intensi-
ty was for each of the indicated tissue elements (Table 1)
graded as − (absent), ± (weak), + (moderate), or ++
(strong).
Cell lines
16HBE 14o- (human bronchial epithelial cell line, a gift of
Prof. D.C. Gruenert, University of Vermont, San Francisco,
CA, USA) and A549 (alveolar type II epithelium-like cell
line, American Type Culture Collection, Rockville, MD,
USA) cells were cultured in Earle's MEM (BioWhittaker
Europe BV, Cambrex, Verviers, Belgium) and RPMI 1640
(BioWhittaker), respectively. Both culture media were
supplemented with 10% heat inactivated fetal bovine serum
(BioWhittaker), L-glutamine (2 mM, BioWhittaker), strep-
tomycin (100 µg/ml, BioWhittaker), and penicillin (100 U/
ml, BioWhittaker) and cultured at 37°C with 5% CO2.
16HBE and A549 cells were detached by trypsin-EDTA
(BioWhittaker) treatment and cytospins were made. Subse-
quently, these cytospins were incubated with antibodies
against the ADAMs and immunostained as described
above.
Results
Expression of ADAMs in bronchial epithelial cells
The expression of the various ADAMs studied in different
locations of human lung tissue is shown in Table 1 and
illustrated in Fig. 1. There was no difference in expression
patterns in the emphysematous lung tissue when compared
to the normal lung tissue from the other six patients. All
ADAMs were expressed in bronchial epithelium, yet they
have a different distribution between basal and apical cells.
ADAM9, ADAM17, and ADAM19 are predominantly
expressed in the apical part of the epithelium, whereas
ADAM33 expression is higher in basal epithelial cells.
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ADAM10 and ADAM8 are diffusely expressed over the
epithelium. Interestingly, staining for the C-terminal end of
ADAM10 is mainly seen in the apical part, and for the N-
terminal end, this is located in the basal cells of the
epithelium.
To verify our tissue findings, we stained ADAMs on the
bronchial cell line 16HBE (Table 2), illustrated in Fig. 2. In
16HBE cells, ADAM9 and ADAM10 are most strongly
expressed, whereas ADAM33 is weakly expressed. Not all
16HBE cells show expression of all ADAM subdomains;
the percentage and intensity of positive cells are given in
Table 2. Staining for the catalytic site of ADAM19 and
ADAM33 showed no positive cells at all. When comparing
the results of epithelial cell lines and lung tissue, expression
in the 16HBE cell line matches the findings in bronchial
epithelial cells in lung tissue.
Expression of ADAMs in alveolar epithelial cells
All ADAMs are expressed in alveolar epithelium (type II
cells); however, expression of ADAM10 and ADAM19 is
weaker in alveolar than bronchial epithelial cells. ADAM8,
ADAM17, ADAM9, and ADAM33 in contrast are equally
expressed in both epithelial cell types.
In the A549 alveolar epithelial type 2 cell line, almost all
ADAMs are expressed in all cells (Table 2; illustrated in
Fig. 2) although the ADAM33 catalytic site and prodomain
show a minor number (5–10%) of negative cells, and
ADAM 19 catalytic site shows no staining at all. In general,
expression in A549 cells matches the findings in the
alveolar type 2 cells.
Expression of ADAMs in bronchial smooth muscle tissue
The expression of ADAM19 is higher in smooth muscle
than in bronchial epithelial cells, whereas ADAM17 is
equally expressed in smooth muscle and epithelium.
ADAM9, ADAM10, and ADAM33 are also expressed in
smooth muscle tissue, yet with a weaker staining in smooth
muscle cells than in bronchial epithelial cells. ADAM8 is
not expressed in smooth muscle tissue.
Expression of ADAMs in vascular endothelium
ADAM33 is the most strongly expressed ADAM in the
vascular endothelium. Some weak expression of ADAM9,
ADAM10, ADAM17, and ADAM19 is present, yet
endothelial expression of these latter ADAMs is not found
in all subjects.
Expression of ADAMs in inflammatory cells
All ADAMs are uniformly and very profoundly expressed
in interstitial inflammatory cells.
Table 1 Location of expression of ADAMs in human lung tissue









ADAM8 Ectodomain R&D Systems ± ± ± − + −
ADAM9 C-terminal Biogenesis + ± ± ± ++ ±
N-terminal Biogenesis + ± + ± + ±
ADAM10 C-terminal, peptide 732–748 Serotec + −/± ± ± + ±
N-terminal Serotec −/± ++ − − ± −
Catalytic site Biogenesis + + −/± ±/+ + −/±
ADAM17 Cytoplasmic domain, peptide 695–824 R&D ++ + + + + ±
ADAM19 C-terminal Biogenesis + + ± + ++ +
N-terminal Biogenesis + −/± − −/± + +
Catalytic site Biogenesis − − − + ±/+ −/±
ADAM33 N-terminal Serotec −/± + −/± ± + +
Cytoplasmic domain Sigma-Aldrich + + + −/± + +
Cytoplasmic domain Triple Point + + + −/± + +
Catalytic site Sigma-Aldrich −/± ± − −/± + +
Prodomain Sigma-Aldrich −/± + + ± + +
Intensity of staining: ++ strong; + moderate; ± weak; − absent. The antiserum to ADAM8 was raised in goat, all others in rabbit. Company details:
R&D Systems, Minneapolis, MN, USA; Biogenesis, Poole, UK; Serotec, Oxford, UK; Sigma-Aldrich Chemicals, Zwijndrecht, The Netherlands;
Triple Point Diagnostics, Forest Grove, OR, USA. Designation of the antibodies as stated as given by the manufacturers
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Glandular cells and nerves
ADAMs are incidentally expressed in glandular cells and
nerves that are present in some of the specimen.
Discussion
ADAMs have been suggested to play an important role in
lung diseases [11–15]. As a starting point to understand the
role of ADAMs in lung disease, it is important to note that
we have found several ADAMs expressed specifically in
both bronchial epithelium and alveolar type 2 epithelial
cells, interstitial inflammatory cells, smooth muscle, and
endothelium. Individual ADAMs showed specific distribu-
tion patterns in these cell types, whereas some ADAMs
showed remarkable co-localization, suggestive for similar
or mutual interacting functions. ADAM expression in a
human lung bronchial and alveolar type epithelial cell line
confirmed the expression in epithelium in human lung
tissue. Interestingly, several ADAMs had a very topical
(predominantly apical or basal) expression, in bronchial
epithelium, suggesting that the more precise localization of
individual ADAM molecules may signify their functional
relevance.
Given the apical localization in airway epithelial cells,
ADAM17, ADAM19, and ADAM9 may play a role in
early immune defense mechanisms. This is exemplified by
both ADAM17 and ADAM19, which are both capable of
shedding TNF-alpha. ADAM17 plays a key role in this
release of soluble TNF-alpha by cleavage of the membrane-
anchored precursor of TNF-alpha [16–18]. TNF-alpha is a
proinflammatory cytokine and a key mediator in immune
defense with a role in induction and amplification of
inflammation, as a response to external, potential threaten-
ing stimuli. The prominent apical distribution of ADAM17
in the bronchial epithelium may thus enable easy activation
and hence a low threshold for rapid and early release of
TNF-alpha in the airway lumen in the defense to disease-
initiating inhaled substances. In addition, cigarette smoke
exposure of human airway epithelial cells has been shown
to lead to ADAM17-mediated release of amphiregulin,
which is a ligand for the epidermal growth factor receptor
(EGFR) [19]. This can be of clinical relevance since
stimulation of EGFR on epithelial cells contributes to
mucus production and epithelial cell proliferation.
ADAM19 can, besides TNF-alpha, release tumor necro-
sis factor-related activation-induced cytokine (TRANCE)
[20]. TRANCE is part of the tumor necrosis factor
superfamily and has an immunity-modulating role as well.
The joint apical expression of ADAM17 and ADAM19 is
of interest and raises the question of whether this represents
ability of coordinated action of the two molecules or that
the regulation of each molecule is individually organized
and may thus indicate their different roles in pathogenesis
of disease. ADAM17, but in particular ADAM19, was also
strongly expressed in smooth muscle. It is conceivable that
particularly with chronic airway wall inflammation, as in
asthma, these ADAMs may become activated and contrib-
ute to the perpetuation of the inflammatory process.
ADAM9, which also is apically expressed in epithelial
cells, has a quite different function. It is capable of
shedding of heparin-binding epidermal growth factor (HB-
EGF) from bronchial epithelial cells via protein kinase C-
delta (PKC-delta) activation [21]. HB-EGF is an important
growth factor, not only for epithelial cells but also for
smooth muscle cells and fibroblasts. This particular apical
localization could then represent low threshold ability to
early tissue (epithelial) repair, in conjunction with the other
local defense mechanisms at the epithelial interface.
Furthermore, ADAM9-mediated cellular adhesion by integ-
rin binding has been described in fibroblasts, which leads to
induction of fibroblast motility [22]. This capacity suggests
Table 2 Expression of ADAMs in a human bronchial and a human
alveolar epithelial cell line
ADAM Designation 16HBE
(% of total cells)
A549
(% of total cells)
ADAM8 Ectodomain + (100%) + (100)
ADAM9 C-terminal ++ (60);+(40) + (100)
N-terminal + (100) + (100)
ADAM10 C-terminal ++ (60);+(40) + (100)
N-terminal ++ (10);+(80);±(10) ± (100)
Catalytic site + (80) + (100)
ADAM17 Cytoplasmic
domain
+ (70) + (100)
ADAM19 C-terminal + (50) + (100)
N-terminal + (50) ± (100)
Catalytic site − −
ADAM33 N-terminal ± (70) + (100)
Cytoplasmic
domain
± (60) + (100)
Catalytic site − + (90)
Prodomain + (80) + (95)
Intensity of staining: ++ strong; + moderate; ± weak; − absent
Fig. 1 Expression of ADAMs in normal human lung, immunostain-
ing with antibodies designated to different domains of ADAMs (as
indicated by manufacturers): a ADAM8 ectodomain, b ADAM10 N-
terminal domain, c ADAM10 catalytic site, d ADAM17 cytoplasmic
domain, e ADAM19 catalytic site, f ADAM19 N-terminal domain, g
ADAM33 prodomain, h ADAM33 N-terminal domain, i ADAM33
cytoplasmic domain. Note specific localization patterns in different
tissue compartments, in particular in different parts of the bronchial
epithelium (immunoperoxidase, original magnification ×200)
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that ADAM9 also may play a role in remodeling of the
airway wall by regulating motility and migration of
fibroblasts and smooth muscle cells.
ADAM10 was diffusely expressed in the bronchial
epithelium, and the N-terminal domain showed especially
strong staining in basal epithelial cells. ADAM10 was also
weakly expressed in smooth muscle. Similar to ADAM9,
ADAM10 is capable of HB-EGF shedding. Considering the
differences in distribution between these two ADAMs, it is
tempting to speculate that once repair has set in by
activating apically located ADAM9, ADAM10 in basal
cells may be responsible for sustained repair effects,
possibly also affecting underlying submucosal structures.
Human ADAM8 has been clustered as a human
leukocyte differentiation antigen, CD156, and is thought
to play a role in cell adhesion and infiltration of
inflammatory cells [23, 24]. ADAM8 was expressed in
bronchial and alveolar type II epithelium and interstitial
inflammatory cells, predominantly with morphology of
neutrophils and macrophages, without smooth muscle
expression. These findings are consistent with its published
expression in the epithelium and increased gene transcrip-
tion in peribronchial and perivascular inflammatory cells in
an allergen induced murine model of asthma [5]. ADAM8
can cleave CD23, the low-affinity IgE receptor (FcεRIIb)
[25], which is involved in up regulation of IL-4 induced
synthesis of IgE in B-cells [26]. CD23 shedding would
counteract IgE-mediated immune responses, next to induc-
ing release of proinflammatory mediators from macro-
phages [27].
ADAM33 was the only ADAM that was predominantly
(and strongly) expressed in the basal cells of bronchial
epithelium (Fig. 1g, h, i). Furthermore, ADAM33 was
expressed in bronchial smooth muscle. A recent study
showed several SNPs in the ADAM33 gene to be associated
with susceptibility of asthma and bronchial hyperrespon-
siveness [6]. The latter study showed ADAM33 to be
expressed in human pulmonary fibroblasts and bronchial
smooth muscle tissue, yet not in epithelial cells. Our
findings are in line with more recent publications that
Fig. 2 Expression of ADAMs in bronchial epithelial cell line 16HBE (a, c, e) and alveolar epithelial cell line A549 (b, d, f): a, b ADAM17
cytoplasmic domain; c, d ADAM33 prodomain; e, f ADAM33 N-terminal domain (immunoperoxidase)
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showed ADAM33 to be localized in epithelium [8, 28].
Low mRNA levels of ADAM33 are shown in bronchial
biopsies although no mRNA was found in epithelial cells
from bronchial brushes [29]. Considering our present
findings, the latter might be explained by the content of
the brushes, in which generally abundant ciliated cells and
little basal epithelial cells are present. Yang et al. recently
described a lack of ADAM33 mRNA in bronchial
epithelium samples [30]. They suggested ADAM33 repres-
sion by a cell type-selective expression of ADAM33, which
was epigenetically controlled by DNA methylation.
Our findings of basal epithelial cell expression of
ADAM33 support its possible involvement in remodeling
process, as in asthma [31]. This may well be initiated by
shedding of c-kit ligand. Not only ADAM33 [32] but also
ADAM8 [33], ADAM9 [34], ADAM17 [35, 36], and
ADAM19 [20] are capable of shedding of c-kit ligand, also
known as stem cell factor (SCF). SCF plays, apart from its
main role as hemopoietic growth factor, a role in recruit-
ment and in maturation of mast cell progenitors [37],
sustaining the survival and maintaining phenotypic proper-
ties of mast cells in mucosal tissues [38, 39]. Furthermore,
SCF may play a role in eosinophil migration and/or
retention in activated tissue compartments [31], given its
expression on human peripheral blood cells. Eosinophils
express a functional c-kit receptor that stimulates very late
antigen 4 (VLA-4)-mediated cell adhesion to fibronectin
and vascular cell adhesion molecule 1 (VCAM-1). As mast
cells and eosinophils are thought to play a key role in the
pathogenesis of asthma [40, 41] and possibly also to be
implicated in COPD [42, 43], the extensive presence of
ADAMs capable of release of c-kit ligand in the airways
suggests a regulatory role for these molecules in manifes-
tation of these diseases.
Another issue of importance is that a large number of
alternatively spliced forms of ADAM33 have been identi-
fied [44, 45]. Some show structural similarity to a synthetic
ADAM12-S that induces myogenesis [46], in turn suggest-
ing ADAM33 to be able to induce airway smooth muscle
proliferation and hypertrophy [44].
Interestingly, strong expression of ADAM33 was ob-
served in vascular endothelial cells, whereas other ADAMs
were more weakly expressed. This may reflect their role in
adhesion, extravasation, and possibly activation of inflam-
matory cells, especially eosinophils. Furthermore, it might
contribute to angiogenesis, which is thought to play a role
in asthma and COPD as well [47, 48]. Furthermore,
angiogenesis is important in tumor development; EGFR-
signaling of ADAMs may contribute in this way [3].
We used commercially available antibodies that are
designed to bind to different domains of the ADAM
proteins. We found similar localization in expression of
different antibodies to subdomains of the same ADAM and
for some, like ADAM33, also for different antibodies to the
same (cytoplasmic) subdomain. Interestingly, there is a lack
of staining for the catalytic (metalloproteinase) site of
ADAM19 and ADAM33, which may implicate that these
ADAMs are lacking the metalloproteinase site and there-
fore are present in an inactive form. For ADAM33, there is
suggestive evidence that this is indeed the case since
alternative splice variants have been described that mostly
lack the metalloproteinase site [44].
Our present study is the first to investigate expression of
several ADAM proteins in lung tissue and discusses the
findings as to their putative role in the pathogenesis of
respiratory diseases. As emphysematous lung tissue shows
a similar expression pattern as the other lung tissues from
patients that underwent surgery for lung cancer, there seems
to be no obvious effect of the lung tumors on the lung
tissue with respect to ADAMs expression. Clearly, this
survey should be expanded, including much more diseased
lung tissue to get further information about possible
ADAMs variations that may play a role in lung disease.
ADAMs appear to have a typical, specific distribution over
the bronchial epithelium and other parts of the bronchial
wall like smooth muscle and vascular endothelium. This
specific localization of ADAMs, especially in the apical
and basal epithelial cells, is interesting as to their individual
and joint contribution toward defense against inhaled
substances. Given the current knowledge on their functional
properties, the distribution suggests that ADAMs play a
main regulatory role in the first line of defense at the
epithelial barrier by coordinated release of proinflammatory
mediators as well as in remodeling and tissue repair by
topic release of various growth factors. A next step is to
dissect the exact functional role of ADAMs and subtle
functional expression differences of ADAMs and their
splice variants in the development and progression of
pulmonary diseases.
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